This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs
by Swarup Gupta
The index enjoyed quite a positive week even as a yield curve inversion weighed on broader markets.
Axsome's Depression Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group
by Zacks Equity Research
J&J (JNJ) submits sBLA seeking approval for Darzalex combination regimen in newly-diagnosed, transplant eligible multiple myeloma patient population
3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses solid growth attributes, which could help it handily outperform the market.
Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million
by Zacks Equity Research
Bayer (BAYRY) and partner Johnson & Johnson settle about 25,000 claims over blood thinner, Xarelto for $775 million.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $136.61, marking a -0.22% move from the previous day.
J&J Files Application for Darzalex Label Expansion in Europe
by Zacks Equity Research
J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.
Cooper Companies' (COO) CooperVision Gains Momentum Globally
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.
Alkermes Focuses on Pipeline, Depends on Partners for Funds
by Zacks Equity Research
Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
by Zacks Equity Research
FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $137.35, moving -0.19% from the previous trading session.
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
by Zacks Equity Research
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Company News For Mar 15, 2019
by Zacks Equity Research
Companies In The News Are: BA, DG, JNJ, WAGE
J&J Seeks Approval for Darzalex in Expanded Patient Group
by Zacks Equity Research
J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.
Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study
by Zacks Equity Research
Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $138.56, marking a +0.36% move from the previous day.
Bayer Submits Application in EU for Prostate Cancer Drug
by Zacks Equity Research
Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
Can Smart Beta & Factor ETFs Beat the Market?
by Neena Mishra
Here is what investors need to know about smart beta and factor strategies that combine the best aspects of active and passive investing.
Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs
by Zacks Equity Research
J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.